View Older Stories View More Recent Stories

Nov 9, 2025 05:00PM Merck's experimental oral cholesterol drug shows promise in genetic disorder trial
Nov 9, 2025 05:00PM Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
Nov 8, 2025 02:30PM Merck's oral PCSK9 inhibitor shows 55.8% cholesterol reduction
Nov 8, 2025 02:30PM Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Nov 4, 2025 06:50AM Merck receives $700 million from Blackstone for cancer drug development
Nov 4, 2025 06:50AM Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
Nov 4, 2025 06:45AM Merck assumes full rights to MK-8690 drug after $150 million Falk deal
Nov 4, 2025 06:45AM Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
Oct 29, 2025 07:00AM Merck and Eisai discontinue liver cancer trial after survival endpoint missed
Oct 29, 2025 07:00AM Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 29, 2025 06:45AM European Commission approves Merck's KEYTRUDA for head and neck cancer treatment
Oct 29, 2025 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CP
Oct 28, 2025 08:00AM MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
Oct 28, 2025 06:46AM Merck drug combination meets cancer trial endpoint in kidney cancer study
Oct 28, 2025 06:45AM Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Neph
Oct 28, 2025 06:30AM WELIREG plus LENVIMA meets key endpoint in kidney cancer trial
Oct 28, 2025 06:30AM Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carc
Oct 27, 2025 06:45AM FDA expands WINREVAIR approval to reduce death and hospitalization risk in PAH
Oct 27, 2025 06:45AM U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
Oct 23, 2025 06:45AM Merck to present phase 3 results for oral PCSK9 inhibitor at AHA meeting
Oct 23, 2025 06:45AM Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
Oct 23, 2025 06:00AM FDA grants priority review for Merck's KEYTRUDA cancer treatments
Oct 23, 2025 06:00AM FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain
Oct 21, 2025 06:45AM Merck presents data on pneumococcal vaccine coverage at IDWeek
Oct 21, 2025 06:45AM Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
Oct 20, 2025 08:46AM Merck KEYTRUDA shows long-term survival benefits in lung cancer patients
Oct 20, 2025 08:45AM KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
Oct 20, 2025 06:45AM Merck begins construction of $3 billion manufacturing facility in Virginia
Oct 20, 2025 06:45AM Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
Oct 19, 2025 08:45AM Daiichi Sankyo and Merck's ovarian cancer drug shows 50.5% response rate
Oct 19, 2025 08:45AM Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
Oct 18, 2025 10:35AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
Oct 18, 2025 10:30AM KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
Oct 18, 2025 06:00AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Ba
Oct 16, 2025 06:45AM Merck KEYNOTE-B96 trial shows survival benefit in ovarian cancer patients
Oct 16, 2025 06:45AM Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
Oct 15, 2025 08:01AM MilliporeSigma to acquire JSR Life Sciences chromatography business
Oct 15, 2025 08:00AM MilliporeSigma to Acquire Chromatography Business of JSR Life Sciences, Expanding Protein A Capabilities and Downstream Portfolio
Oct 15, 2025 06:45AM Merck presents new HIV drug trial data on weight and lipid effects
Oct 15, 2025 06:45AM Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infecti
Oct 9, 2025 07:00AM Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
Oct 9, 2025 06:45AM Merck presents cancer research data at ESMO 2025 congress
Oct 9, 2025 06:45AM Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
Oct 7, 2025 06:45AM Merck completes $10 billion acquisition of Verona Pharma
Oct 7, 2025 06:45AM Merck Completes Acquisition of Verona Pharma
Oct 6, 2025 06:45AM Merck starts phase 2b trials for tulisokibart in three new conditions
Oct 6, 2025 06:45AM Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
Oct 1, 2025 06:45AM Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
Sep 30, 2025 03:39AM Merck's WINREVAIR reduces clinical worsening events by 76% in early PAH patients
Sep 30, 2025 03:39AM WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
View More Recent Stories View Older Stories